Insmed (NASDAQ:INSM) COO Roger Adsett Sells 1,429 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 1,429 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $173.33, for a total value of $247,688.57. Following the completion of the sale, the chief operating officer directly owned 110,462 shares of the company’s stock, valued at approximately $19,146,378.46. This trade represents a 1.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Roger Adsett also recently made the following trade(s):

• On Thursday, January 8th, Roger Adsett sold 2,059 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total transaction of $358,616.03.
• On Wednesday, January 7th, Roger Adsett sold 802 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $140,406.14.

Insmed Stock Down 3.3%

Insmed stock opened at $170.27 on Friday. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $212.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. The firm has a market cap of $36.31 billion, a PE ratio of -27.51 and a beta of 1.08. The firm’s 50 day moving average price is $190.31 and its two-hundred day moving average price is $151.37.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The company had revenue of $142.34 million for the quarter, compared to analysts’ expectations of $114.33 million. During the same quarter in the prior year, the firm earned ($1.27) earnings per share. The company’s revenue was up 52.4% on a year-over-year basis. On average, research analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Company update: Insmed reported strong unaudited revenues tied to its commercial launches—BRINSUPRI posted roughly $144.6M in total revenue in its first full quarter and ~$172.7M for full-year 2025; ARIKAYCE generated ~ $433.8M for 2025, exceeding the top end of prior guidance. Management provided 2026 ARIKAYCE guidance of $450M–$470M, signaling continued commercial momentum. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Pipeline timing: Management updated clinical timelines — ENCORE (ARIKAYCE Phase 3) topline now expected March/April 2026 and CEDAR (brensocatib Phase 2b in HS) topline anticipated in Q2 2026. These upcoming readouts are material catalysts but the shifted timing may compress near-term volatility. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: New Phase‑3 starts: Insmed initiated the PALM‑ILD Phase 3 for TPIP in PH‑ILD in Q4 2025 and plans further Phase 3 studies in PAH, PPF and IPF in 2026 — a positive R&D cadence but one that increases near-term spend and execution risk. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Media attention: Jim Cramer flagged Insmed as “worth keeping an eye on,” which can boost retail interest and liquidity but is not a fundamental endorsement. Jim Cramer on Insmed
• Negative Sentiment: Insider selling: Multiple executives (CEO, CFO, COO and others) have recently sold shares across Jan. 6–8, and a report flagged approximately $15.29M in insider sales—activity that can signal near-term profit-taking or create negative perception among investors. Insider Selling: Insmed Insider Sells $15,293,208.00 in Stock
• Negative Sentiment: Investor litigation alert: Pomerantz LLP launched an investor investigation related to Insmed, which introduces potential legal and reputational risk and could weigh on sentiment until clarified. Pomerantz Investigates Claims On Behalf of Investors of Insmed

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on INSM. Royal Bank Of Canada dropped their price target on shares of Insmed from $215.00 to $195.00 and set an “outperform” rating on the stock in a research note on Thursday, December 18th. Jefferies Financial Group set a $269.00 target price on shares of Insmed in a research report on Wednesday, December 10th. Leerink Partners reaffirmed an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Cowen set a $241.00 price target on Insmed in a research note on Thursday, December 18th. Finally, Bank of America boosted their target price on Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $205.64.

Institutional Trading of Insmed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INSM. CIBC Private Wealth Group LLC lifted its holdings in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the last quarter. ORG Partners LLC increased its position in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 196 shares during the period. Hilltop National Bank acquired a new position in Insmed during the 2nd quarter valued at $28,000. Stone House Investment Management LLC bought a new stake in Insmed in the 3rd quarter valued at $29,000. Finally, SBI Securities Co. Ltd. boosted its holdings in Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 166 shares during the period.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.